With the amount of healthcare-related information now readily available on the Internet, it is often difficult to differentiate between what is accurate and clinically relevant, and what is not. CollabRx’s mission is to change the practice of medicine by making thought-leader medicine accessible to all––providing actionable medical and scientific content to drive informed treatment decision-making.
Designed with all healthcare participants in mind, CollabRx’s products and services are tailored to fit the needs of patients and healthcare professionals alike. By providing the industry with interactive and highly credible Web-based and mobile platforms and applications, users now have unlimited access to the most up-to-date information on drugs, diagnostics, and clinical trials associated with specific molecular profiles.
Delivering Comprehensive Solutions
CollabRx develops products that inform treatment planning by changing the way medical and scientific information is organized, interpreted and disseminated with the goal of providing high value knowledge in an easily accessible form.
CollabRx clinical products are point-of-care electronic resources to assist oncologists, other physicians and health care professionals, and cancer patients in creating a personalized treatment plan by leveraging the unique genetic profiles of a given patient’s tumor.
The CancerRx™ app is a mobile clinical decision support resource designed to help physicians and their patients navigate the complex landscape of oncology therapeutic options. It currently offers expert-vetted guidance of treatment options (i.e., drugs, tumor genetic tests) for lung cancer, melanoma, metastatic breast cancer and colorectal cancer based on tumor genetic profiles, stage, and histology in addition to other important clinical parameters such as treatment history. In addition to treatment options based on the current standard of care, CancerRx helps physicians and patients identify the most relevant clinical trials of investigational therapies, and provides summaries and links to clinical findings published in top tier medical journals and presented at national conferences for oncologists and other physicians involved in the care of cancer patients. A special feature of CancerRx is a daily oncology newsfeed from MedPage Today, all with real-time over the air updates.
All knowledge is developed in close collaboration with CollabRx’s expert advisory network, which is composed of over 75 leading physicians, scientists, and researchers from the nation’s most prestigious academic and medical institutions as well as thought leaders spanning diverse backgrounds.
Therapy Finder™ Applications
Therapy Finders are a series of Web-based expert system applications (“apps”) that enable physicians and their patients to learn which tests should be considered for tumor molecular analysis and how to use the results of those tests in evaluating therapy options including approved and investigational drugs and clinical trials. The rationale for knowledge delivered via CollabRx Therapy Finders is transparent, associated with peer-reviewed publications, and generated by CollabRx scientific staff in collaboration with editorial boards of leading clinical practitioners.
Therapy Finder apps are freely accessible, provided for specific cancer types, and delivered in a form optimized for health care professionals (Professional version) and patients and caregivers (Patient version). The Therapy Finder – Professional version is currently available for melanoma, colorectal cancer, and lung cancer. Other cancer types and Patient versions are in development. Also in development is an oncology-specific mobile app that will incorporate the Therapy Finders and ultimately serve as a comprehensive point of care resource for physicians and patients to obtain highly credible, expert-vetted and dynamically updated information to guide cancer treatment planning. Read the press release.
CollabRx is developing Web-based resources and apps to provide expert-vetted interpretation of molecular cancer panels, including clinical next-generation sequencing of tumors, in collaboration with our Pan Cancer molecular oncology Editorial Board.
Genetic Variant Annotation™ (GVA™) Service
The CollabRx GVA Service provides for a fully automated and scalable medical informatics solution to inform patient treatment planning by seamlessly pairing the results of genetic sequencing tests (generated on any platform) with clinically actionable and dynamically updated knowledge (provided by CollabRx in the form of interpretive reports). Knowledge contained within GVA reports includes the clinical impact of specific genetic profiles and associated therapeutic strategies such as drugs and clinical trials. This content leverages the CollabRx semantic integration platform, a proprietary technology that enables CollabRx scientists and physicians to dynamically update the company’s knowledge base with the latest medical and scientific data available in the public domain. This knowledge is further contextualized in collaboration with CollabRx’s large and growing formal network of over 75 leading clinical practitioners in the U.S. and Europe.
Disease and Biomarker Coverage*
The GVA Service is currently available in oncology for all adult solid tumor types to support the clinical interpretation of tests to elucidate tumor mutation profiles generated on any testing platform, including next generation sequencing (NGS) devices. Tumor genetic alterations currently interpreted by the GVA Service include single base pair substitutions (missense and nonsense mutations) and nucleotide insertions and deletions (frameshift mutations). Support for other types of tumors (e.g., hematological malignancies) and genetic alterations (e.g., gene copy number variation (CNV), etc.) are in late stage development. There are hundreds of biomarkers and thousands of genetic alterations, drugs, and annotated clinical trials currently in the GVA knowledge base, all of which are linked to summary level information presented in a cancer type specific manner. This information directly supports clinical decision-making and includes expert-vetted statements describing clinical impact, therapeutic strategies, and potential drugs and clinical trials to consider during cancer treatment planning. Clinical guidelines, citations from the peer-reviewed medical and scientific literature, and other publicly available sources of information are provided in support of all information contained in GVA reports.
*Download an overview of the GVA Service. Detailed specifications and sample GVA reports are available upon request.
- One time set-up fee, annual maintenance fee, per-test fee
Access via API
Fully automated process; ideal for higher test volumes or larger labs
Access via Web portal
Semi-automated process; ideal for lower test volumes or smaller labs
Click here to see partner laboratories or contact us to to learn more about the GVA Service or other CollabRx products and services.
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low intensity acoustic technology.
The company’s patented technology allows for creation of miniature transducers that transmit low-frequency, low-intensity ultrasound through flexible materials surfaces. This unique development may be utilized for a variety of additional medical applications requiring low cost therapeutic ultrasound qualities.
The company’s PainShield™ MD product has gained CE Mark certification and FDA clearance while the UroShield™ is currently CE mark certified.
NanoVibronix Inc. is located in Long Island, NY. Its subsidiary, NanoVibronix Ltd. is located in Nesher, Israel.